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Abstract Background In this study, we have evaluated hepatotoxicity, secondary cytokine produc-
tion and hepatic acute-phase response (APR) in patients who underwent isolated hepatic
perfusion (IHP) with tumour necrosis factor (TNF) a and melphalan for irresectable
colorectal liver metastases.
Design An extracorporeal veno-venous bypass was used to shunt blood from the lower body
and intestines to the heart. Inflow catheters were placed in the hepatic artery and portal vein,
and an outflow catheter in the inferior caval vein. The liver was perfused for 60 min with
0·4 mg of TNF-a plus 1 mg kg¹1 melphalan (IHPTM group, n ¼ 6) or 1 mg kg
¹1 melphalan
(IHPM group, n ¼ 3). The liver was washed with macrodex before restoring vascular
continuity.
Results After the washout procedure, a TNF-a peak (169 6 38 pg mL¹1) was demon-
strated in the IHPTM group only. Both groups demonstrated peak levels of interleukin 6
(IL-6) in the perfusate as well as systemically. These were significantly higher in the IHPTM
group. Acute-phase protein (APP) levels followed a similar pattern as has been demonstrated
after major surgery, with no significant differences between both groups. The addition of
TNF-a to the perfusate did not lead to a significant difference in APP levels and the time
course between groups.
Conclusions IHP with TNF and melphalan is followed by a transient systemic peak of TNF
directly after liver washout. Secondary IL-6 induction was seen in the present study after
IHP with and without TNF, which was highest when TNF was added. This phenomenon
cannot be extrapolated to APP induction, which appeared unaffected by the addition of
TNF, presumably because the surgical procedure itself already causes maximal stimulation
of APP production.
Keywords Acute-phase proteins, isolated hepatic perfusion, interleukin 6, tumour necrosis
factor a.
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Introduction
The acute-phase response (APR) is a general systemic
reaction induced by injury or various kinds of inflammatory
states such as burns, infection or surgical procedures. As
part of this reaction, the liver responds to several mediators
by the increased synthesis of a series of glycoproteins called
acute-phase proteins (APPs). The function of the APPs is
pleiotropic: they may both mediate and inhibit inflamma-
tion, scavenge free oxygen radicals, act as transport pro-
teins for products of the inflammatory process, or have an
active role in tissue repair and remodelling.
Both tumour necrosis factor a (TNF-a ) and interleukin
6 (IL-6) have been shown to induce the APP synthesis of
the liver, of which the latter seems to be the major inducer
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and mediator of this APP production [1–4]. TNF-a
derives its name from the observation that it can
cause haemorrhagic necrosis of tumours. However, TNF-
a is also known to be an important mediator in shock.
Systemic administration of small amounts of TNF-a leads
to influenza-like symptoms; at higher dose levels septic
shock syndrome develops, characterized by pulmonary
oedema, adult respiratory distress syndrome and severe
inflammatory response syndrome. For this reason, many
phase I and II trials studying the systemic administration of
TNF-a have failed to reproduce the experimental successes
because the severe, systemic toxic side-effects of TNF-a
limited the usable dose of TNF-a to a level at which no
effective anti-tumour activity could be seen [5–7].
It has been shown recently that this concentration
gap can be overcome by the application of cytostatic
drugs in isolated perfusion systems. These allow safe
increase in doses to >20 · the systemic maximum tolerated
dose (MTD) [8]. This also holds true for the application of
TNF-a in such systems. It has become firmly established
that TNF-a can be applied safely and successfully in
isolated limb perfusion (ILP) both in melanoma patients
[9] and in patients with irresectable soft tissue sarcomas
[10,11]. Furthermore, this remarkable anti-tumour effec-
tivity of TNF-a in combination with melphalan, proved to
be effective against a wide range of histologies [5].
The results of the ILP studies led to the development of
isolated perfusion of other organs, such as isolated hepatic
perfusion (IHP) [12,13]. With this technique, the liver
circulation is completely separated from the systemic cir-
culation, thus allowing high drug levels within the liver
while keeping systemic exposure low. However, unlike
limbs, the liver is a metabolically active organ that contains
a large amount of tissue macrophages, the Kupffer cells. As
Kupffer cells are known to release various cytokines in
response to TNF-a, it could therefore be speculated that
IHP with TNF-a might induce considerable (hepato)toxi-
city. Therefore, we were interested in the effects of IHP
with TNF-a on hepatic function, secondary cytokine pro-
duction and hepatic APR. To obtain further insight, we
evaluated patients who underwent IHP with TNF-a and
melphalan for colorectal metastases confined to the liver.
The APR was evaluated regarding the levels and time
dependency of TNF-a, IL-6, the APP C-reactive protein
(CRP), a1-acidglycoprotein, a1-antitrypsin and transferrin.
Methods
IHP patient groups
From January to June 1995, nine patients underwent IHP
for irresectable hepatic colorectal metastases. All gave
informed consent before treatment in protocols approved
by the hospitals’ ethics committees. The study was carried
out in accordance with the principles of the Declaration of
Helsinki, as revised in Hong Kong in 1989. There were six
men and three women with a mean age of 59·8 years (range
49–65 years). Inclusion criteria for IHP with TNF-a and
melphalan included histological evidence of irresectable
metastases of colorectal origin confined to the liver, Kar-
novsky performance status of >80%. Exclusion criteria
included extrahepatic malignant disease, >50% hepatic
tissue replacement by tumour, liver cirrhosis, signs of
significant hepatic dysfunction (abnormal levels of ASAT,
ALAT or alkaline phosphatase > 2· norm) and ascites or
portal hypertension.
ILP technique
The procedure of IHP has been described elsewhere [12].
Briefly, the vasculature of the liver was dissected free and
isolated. After systemic heparinization (200 U kg¹1), an
extracorporeal veno-venous bypass (VVB) circuit (aided
by a passive centrifugal pump) was created to shunt
mesenteric, renal and lower extremity blood around the
liver to the heart. Next, inflow catheters were placed in the
portal vein and hepatic artery, and an outflow catheter was
placed in the infrahepatic inferior caval vein. These cathe-
ters were connected to a heart–lung machine, and the
vascular isolation was completed by clamping the suprahe-
patic inferior caval vein and the suprarenal inferior caval
vein. The liver was then perfused with a hyperthermic
(> 38 8C) perfusate consisting of a mixture of saline and
erythrocytes. Once a stable perfusion was attained, leakage
from the perfusion circuit into the systemic circulation
was measured by the addition of 200 mCi [131I]-albumin
into the perfusate and the continuous monitoring of radio-
activity scintillation probes placed over the perfusate reser-
voir and the VVB. The leak rate was monitored for the
duration of the perfusion and if the cumulative leak was
greater than 15%, the perfusion would be halted and the
perfusate flushed from the circuit. After the absence of
leakage was confirmed, drugs (see treatment schedule)
were administered as a bolus into the arterial line of the
perfusion circuit. After a 60-min perfusion, the liver was
washed thoroughly with a mixture of saline and macrodex,
decannulated, and vascular continuity restored. Heparin
was reversed with 1 mg kg¹1 protamine sulphate (Novo-
Nordisk, Rud, Norway) injection. Post-operatively, the
patients were monitored at the intensive care unit for
at least 48 h, primarily to evaluate evidence of systemic
toxicity due to rhTNF-a.
Drugs
Recombinant human TNF-a (0·2 mg per ampoule) was
a kind gift from Boehringer Ingelheim, Ingelheim am
Rhein, Germany. The cytostatic drug melphalan (Alkeran)
was obtained as a sterile powder (100 mg), which
was dissolved aseptically using solvent and diluent by
Burroughs Wellcome, London, UK.
Treatment schedule
In six patients (IHPTM group), 0·4 mg of TNF-a was
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administered as a bolus; melphalan (1 mg kg¹1) was given
directly after the TNF-a bolus. In three patients (IHPM
group) only melphalan (1 mg kg¹1) was administered.
Sampling schedule
Blood samples were collected from a peripheral vein
in siliconized 5-mL Vacutainer tubes (Becton Dickinson,
Plymouth, UK) containing EDTA (10 nmol L¹1) and soy-
bean trypsin inhibitor (100 mg L¹1) and benzamidine
(10 nmol L¹1) (Sigma Chemicals, Detroit, MI, USA).
Samples were centrifuged immediately after collection, at
5000 rpm. for 5 min. Supernatants were stored at ¹70 8C
until analysis. Perfusate was sampled at t ¼ 0 (i.e. upon
drug administration), 10, 20, 30, 40, 50 and 60 min.
Systemic plasma samples were collected the day before
IHP, during IHP at t ¼ 0, 30 and 60 min and post perfusion
(after release of the inferior caval vein clamp) at t ¼ 1, 5, 10,
20, 30, 60, 120 and 240 min, days 1, 3 and 7, and weekly
thereafter, until 3 weeks post-operatively.
Assays
TNF-a levels were measured by a sandwich-type enzyme-
linked immunosorbent assay (ELISA) using two mono-
clonal antibodies (Department of Immune Reagents, Cen-
tral Laboratory of Blood Transfusion, Amsterdam, The
Netherlands) raised against recombinant human TNF-a
(courtesy of D. A. Creasey, Chiron, Emeryville, CA, USA).
One MAb (MAb CLB-TNF-a-7) was used for coating at a
concentration of 2 mg mL¹1. The other MAb (MAb CLB-
TNF-a-5) was biotinylated and used in combination with
streptavidin–poly-horseradish peroxidase conjugate (CLB,
Department of Immune Reagent) to detect bound TNF-a.
Stimulated human mononuclear cell supernatant was used
as a standard for comparison with purified recombinant
human TNF-a. Results were expressed as pg mL¹1 by
reference to this standard [14]. The detection limit of this
assay was 10 pg mL¹1.
IL-6 was measured by an ELISA modified from that
described in detail before [15]. Briefly, purified monoclonal
anti-human IL-6 antibody (MAb CLB-IL-6-16) was used
as a capture antibody, and biotinylated sheep antibodies in
combination with streptavidin–poly-horseradish peroxi-
dase conjugate were used to detect bound IL-6. Results
were expressed as pg mL¹1 by reference to a standard
consisting of recombinant human IL-6. Normal healthy
control subjects’ values were >10 pg mL¹1, and the limit of
detection was 5 pg mL¹1.
Acute-phase proteins
CRP, a1-antitrypsin (a1-AT), a1-acidglycoprotein (a1-AG)
and transferrin (TRF) levels were measured by means of a
nephelometric assay [16]. The antisera used were obtained
from the Central Laboratory of the Blood Transfusion
Service (CLB), Amsterdam, The Netherlands. Normal
values (obtained from 100 blood donors) were CRP
< 5 mg L¹1, a1-AT 1·4–3·2 g L
¹1, a1-AG 0·4–1·3 g L
¹1
and TRF 2·3–4·3 g L¹1.
Statistics
Results are expressed as means 6 standard error of the
mean (SEM). Comparison within groups were made by
means of the Friedman non-parametric repeated measures
test or by the Mann–Whitney test when appropriate.
Correlations between maximum levels of parameters were
calculated as Spearmann’s rank correlations. A two-sided
P-value <0·05 was regarded as significant.
Results
Operative procedure
The median duration of the operation was 8 h (range 6–10 h).
In all patients, a stable perfusion was attained. In one
patient, progressive systemic leakage resulted in disconti-
nuation of the IHP after 43 min (cumulative leakage 20%).
In all other patients, no leakage was demonstrated. Three
patients in the IHPTM group died in the immediative post-
operative period as a result of surgical complications of the
operation. As the purpose of this study was to describe APR
in uncomplicated IHP, these patients were excluded.
Survival
In the six evaluable patients, the survival time ranged from
6 to 26 months. The median survival time was 10·3 months
(mean 13·3 months).
Tumour response
The primary efficacy end points in the study were best
tumour response observed [WHO response criteria: com-
plete response (CR), partial response (PR), stable disease
(SD) or progressive disease (PD)] and duration of the best
response, calculated from the date the best response was
observed until the date of progression. Tru-cut hepatic
tissue samples and/or computerized tomography (CT)
scan evaluations were used to describe the best tumour
response. In the IHPTM group five out of six patients
demonstrated CR or PR, and one patient demonstrated
SD. Patients treated with melphalan alone demonstrated
PR or SD. The duration of best response ranged from 17·5
to 32·5 weeks (median 18 weeks).
Toxicity
Toxicity and adverse events were assessed and recorded
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according to the WHO grading system (WHO Adverse
Event Coding Thesaurus) [17].
General toxicity
In the IHPTM group, all patients developed slight fever,
hypotension, pulmonary toxicity and sinus tachycardia,
which was reported as drug related. All patients demon-
strated anaemia and thrombocytopenia (nadirs at day 3),
returning to normal after 10 days post IHP (P >0·05
between groups).
Hepatotoxicity
All patients demonstrated significant initial elevations in
liver enzyme levels, normalizing within the first 2 post-
operative weeks (P> 0·05 between groups). In contrast,
bilirubin and alkaline phosphatase levels increased more
slowly after IHP but remained elevated for a longer period.
Overall, two (IHPTM group) patients demonstrated grade
III and three (IHPTM group) patients grade IVaccording to
the WHO classification (Fig. 1).
Cytokine levels
TNF-a levels
In the perfusate, TNF-a levels in the IHPTM group were
1·8 6 0·5 pg mL¹1 at t ¼ 0 min and increased rapidly to
6·7 6 0·9 · 104 pg mL¹1 at t ¼ 10 min. Thereafter, TNF-a
levels decreased to 3·1 6 0·3 · 104 pg mL¹1 at the end of
IHP (t ¼ 60 min). In the IHPM group TNF-a levels did not
demonstrate any significant changes. (Fig. 2).
Baseline serum TNF-a levels were similar in both
groups, although these levels were higher than normal
(4·3 6 0·5 pg mL¹1 and 4·5 6 1 pg mL¹1 in the IHPTM
and IHPM group respectively). During IHP, TNF-a
levels did not change significantly, indicating that vascular
isolation was effective. However, after washout, TNF-a
levels increased rapidly to a peak value of 169 6 38pgmL¹1 at
t ¼ 1 min in the IHPTM group and normalized within the
next 3 h. In the IHPM group, TNF-a levels demonstrated a
slight increase to 7·2 6 5 pg mL¹1 within the first 30 min
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Figure 1 Time course of liver enzyme levels ASAT (a) and
ALAT (b) as a function of time following IHP. Time is expressed
in days on the x-axis, where ¹1 represents the day before the
operation. Because liver enzyme levels were virtually equal in
both groups, the IHPM group levels are not shown for reasons of
clarity.
Figure 2 Time course of TNF-a levels before, during and after
IHP. (a) Perfusate levels. (b) Systemic levels. D–1, the day
before IHP; 0, 30, 60, 61, 120, 0, 30, 60, 61, 120 min after start
of IHP (61 min represents the time just after vascular restoration,
not shown in the following panels); 9 h, 9 h, after IHP; D1, D3,
D5, D7, first, third, fifth and seventh days after IHP. O–O,
Patients receiving TNF and melphalan; B–B, patients receiving
melphalan alone.
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after IHP. However, this elevation of TNF-a levels in the
IHPM group was not statistically significant (Fig. 2).
Interleukin-6 levels
In the perfusate, baseline IL-6 levels were elevated in both
the IHPTM and IHPM groups (91 6 45 pg mL
¹1 and
94 6 58 pg mL¹1 respectively). During IHP, IL-6 levels
increased over time to 2·1 6 0·7 · 103 pg mL¹1 in the
IHPTM group (P <0·01) and to 227 6 128 pg mL
¹1
(P >0·05) in the IHPM group (P <0·01 between groups,
Fig. 3).
Serum IL-6 levels at the start of the IHP procedure were
elevated in both groups and rose slightly during IHP
(P <0·05 between groups). However, after the washout
procedure, IL-6 levels increased significantly, reaching
the highest levels, 1 h after washout, in the IHPTM group
(P <0·01 between groups). Maximum IL-6 levels were
9·8 6 0·8 · 103 pg mL¹1 and 2·4 6 1 · 103 pg mL¹1 in the
IHPTM and IHPM group respectively. Thereafter, levels
dropped and returned to preoperative levels within the first
post-operative day (Fig. 3).
Acute-phase protein response
C-reactive protein levels started to rise 9 h after washout,
and maximum levels (143 6 3 mg L¹1 and 129 6 4 mg L¹1
in the IHPTM IHPM group respectively) were reached at
the fifth post-operative day. Thereafter, levels dropped and
normalized slowly within the next 2 weeks (P >0·05
between groups, Fig. 4).
From the start of the IHP procedure a1-antitrypsin and
a1-acidglycoprotein levels first decreased in both groups.
At 60 min after washout, levels increased gradually
(P <0·01), and they were still elevated at day 10 (P <0·05
between groups, Fig. 4).
The ‘negative’ APP transferrin levels in both groups
decreased until 30–60 min after washout, whereafter
levels increased to normal values within the first post-
operative days (P< 0·05 between groups, Fig. 4).
Discussion
In this study, we describe the effects of IHP with TNF-a
and melphalan, or melphalan alone, on secondary cytokine
and APP production. After the washout procedure, IHP
was followed by a TNF-a peak in the IHPTM group only,
normalizing within 2 h. TNF-a levels in the melphalan
alone group remained virtually unchanged. In both
groups, peak levels of IL-6 were observed 1 h after the
washout, although levels were significantly higher in those
patients with TNF-a added to the perfusate. IL-6 levels
normalized at day 1 post-operatively. The APP production
followed a pattern similar to that demonstrated after var-
ious kinds of surgery, including major hepatic surgery, with
no differences between both groups.
Despite its promising in vitro anti-tumour effects, the
in vivo administration of TNF-a has been demonstrated to
be accompanied with dose-limiting systemic toxicity at
dose levels at which no amti-tumour effect could be seen.
Furthermore, these phase I and II studies demonstrated
specific organ toxicity with increasing dosages of TNF-a
[6,7]. We were particularly interested in the potential
hepatotoxicity caused by IHP with TNF-a and melphalan.
All our patients displayed moderate transient hepatotoxi-
city as demonstrated by transient elevated hepatic enzymes
(Fig. 1). Since similar elevations were also observed in the
IHPM group, we believe that the addition of TNF-a did not
lead to additional hepatotoxicity. These findings are in
accordance with the results of our experimental IHP pro-
gram in pigs [12]. Therefore, more likely, we think that the
hepatotoxicity encountered in our patients is the result, at
least in part, of the IHP procedure itself.
To avoid systemic exposure to chemotherapeutic agents
or cytokines, the main goal of the isolation perfusion
technique is the complete vascular isolation of the limb or
Figure 3 Time course of IL-6 levels before, during and after
IHP. (a) Perfusate levels. (b) Systemic levels. D–1, the day
before IHP; 0, 30, 60, 120, 0, 30, 60, 120 min after start of
IHP; 9 h, 9 h, after IHP; D1, D3, D5, D7, first, third, fifth
and seventh days after IHP. O–O, Patients receiving TNF and
melphalan; B–B, patients receiving melphalan alone.
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organ. In our study, vascular isolation of the liver
was complete in all patients but one. In this patient,
progressive systemic leakage (cumulative leakage 20%)
led to premature termination of the IHP procedure after
43 min. However, despite this leakage, this patient did not
demonstrate additional toxicity as demonstrated by clinical
and biochemical parameters compared with the other
patients studied. The same observation has been demon-
strated by Pinsky and co-workers [18], who showed that
the outcome of patients with septic shock did not correlate
with peak levels but with the persistence of both TNF-a
and IL-6 levels. In our eight patients without leakage,
systemic TNF-a levels did not change significantly
during IHP, indicating that vascular isolation was com-
plete. After the washout procedure, however, systemic
TNF-a levels in the IHPTM group peaked rapidly and
normalized within the next 2–3 h (Fig. 2). A possible
explanation for this TNF-a peak in the IHPTM group
could be the release of remnant TNF-a in the liver after
the washout procedure, a phenomenon also described in
ILP with TNF-a and melphalan [16,19,20]. However,
peak TNF-a levels in our study were much lower than
those levels in ILP, indicating a more efficient washout
procedure [19,21]. Furthermore, endogenous TNF-a pro-
duction may have attributed to this peak, because surgery,
extracorporeal circulation circuits and intravascular plastic
catheters are known to induce TNF-a [22,23]. However,
the last explanation may be of less importance because
only mild elevation of systemic TNF-a levels could be
demonstrated in the IHPM group (Fig. 2).
TNF-a is also known as a proinflammatory cytokine
able to stimulate the production of several interleukins such
as IL-6. In this study, perfusate IL-6 levels increased
significantly in all patients during IHP, with the highest
levels in the IHPTM group (Fig. 3). The same pattern has
been demonstrated in the perfusate of ILP circuits in
patients with melanoma stage III/IVor irresectable sarcoma
of the limbs, although perfusate IL-6 levels in our patients
(IHPTM group) were much higher at a lower TNF-a dose
[20]. Macrophages are known to produce various cyto-
kines, e.g. IL-6, in response to TNF-a. As the liver contains
the largest amount of fixed tissue macrophages, Kupffer
cells, this induction of IL-6 production by the Kupffer cells
could be an explanation not only for the difference in IL-6
levels between our study groups, but also between IHP and
ILP. Furthermore, all patients demonstrated elevated sys-
temic IL-6 levels at the start of the actual perfusion which
further increased with perfusing time. Several studies
have demonstrated increased IL-6 levels after various
surgical procedures, including hepatic surgery [24–29].
Cruickshank et al. [29] described elevated IL-6 levels in
patients undergoing elective surgery of varying severity.
Levels of IL-6 were shown to increase with the extent
of surgery. Several other studies confirmed this finding
but peak IL-6 levels were usually less than 500 pg mL¹1
[24–29]. In this context, it should be borne in mind that, at
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Figure 4 Time course of C-reactive protein (a), a1-antitrypsin
(b), a1-acidglycoprotein (c) and transferrin (d) levels before,
during and after IHP. Time is expressed on the x-axis as follows:
D–1, the day before IHP; 0, 30, 60, 120, 0, 30, 60, 120 min
after start of IHP; 9 h, 9 h, after IHP; D1, D3, D5, D7,
first, third, fifth and seventh days after IHP. O–O, Patients
receiving TNF and melphalan; B–B, patients receiving melphalan
alone.
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the beginning of the perfusion, patients already had under-
gone a major surgical procedure, with subsequent
increased IL-6 concentrations resembling levels described
in other surgical procedures (Fig. 3, t ¼ 0 min). The slow
initial increase during IHP was followed by a further steep
increase after IHP to a peak at 1 h after the washout
procedure (Fig. 3). Although this peak occurred in both
groups, it was significantly higher in those patients perfused
with TNF-a and melphalan. Since both groups underwent
the same surgical procedure with melphalan, the significant
difference between groups can only be explained by the
addition of TNF-a to the perfusate of the IHPTM group.
The same observation was reported by Thom et al. [20]. In
their study serum IL-6 levels in patients with ILP with
TNF-a, interferon-a and melphalan were significantly
higher than ILP with melphalan alone, with a trend
towards higher IL-6 levels with increased exposure to
TNF-a. Taking into account the aforementioned Kupffer
cell response to TNF-a, both the TNF-a peak after wash-
out in the IHPTM group and the hepatic IL-6 production
could be an explanation for the difference in systemic peak
IL-6 levels.
An important function of the liver is the production of
so-called APPs in response to various stimuli. In all our
patients a clear APR could be observed. Levels of all
proteins first decreased, probably caused by haemodilution
in combination with extravasation after the washout pro-
cedure. Thereafter the negative APPs normalized, whereas
the positive APPs started to increase and remained elevated
for at least 2 weeks with the exception of CRP, which
normalized within this period (Fig. 4). Furthermore,
there were no significant differences in APP levels between
both groups. Several in vitro and in vivo studies demon-
strated that IL-6 is secreted in the early stages of the APR
and is the main mediator of the hepatic production of
APPs such as a1-AG, a1-ATand CRP [2,4]. To emphasize
the central role of IL-6, in vivo studies have revealed
clear correlations between IL-6 and several APP levels
[3,30–33]. Since in our study significant differences in
systemic IL-6 levels were demonstrated, we speculated
that this might lead to a different APP production profile
between groups. In contrast, in our study, there were no
significant differences in APP profiles nor peak levels
between groups. Moreover, we could not demonstrate a
significant correlation between peak IL-6 and CRP levels.
Instead, the APP pattern, including peak levels, as
described here is similar to patterns demonstrated after
elective surgery of various extent, including ILP
[16,31,32]. A possible explanation for the identical profile
in both groups could be that the IHP, as a major surgical
procedure (and identical in both groups), already caused a
maximal induction of the APPs by the liver. Consequently,
the addition of TNF-a to the perfusate, with subsequent
short-lived systemic TNF-a peak and resulting IL-6 peak
could not further influence the APR. Thus, the conditions
under which TNF-a induced IL-6 production occurs may
be essential to the extent to which the hepatic APR is
induced [34].
In conclusion, IHP with TNF and melphalan is followed
by a transient systemic peak of TNF directly after liver
washout. Secondary IL-6 induction was seen in the present
study after IHP with and without TNF, which was highest
when TNF was added. This phenomenon cannot be
extrapolated to APP induction, which appeared unaffected
by the addition of TNF, presumably because the surgical
procedure itself already causes maximal stimulation of APP
production.
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